Clinical Trials

Nintedanib Gains Promising Innovative Medicine Status in the UK

It was recently announced that the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) designated nintedanib, an oral triple angiokinase inhibitor by Boehringer Ingelheim, as a Promising Innovative Medicine (PIM). Nintedanib is not yet available to malignant pleural #mesothelioma patients in the UK, but with this designation, the drug could be available to patients […]

Read More